JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a report issued on Tuesday morning,Benzinga reports. The firm issued an overweight rating and a $30.00 price objective on the stock.
Separately, Leerink Partners assumed coverage on Maze Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $28.00 price objective for the company. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $25.67.
View Our Latest Stock Report on MAZE
Maze Therapeutics Trading Down 3.9 %
Shares of NASDAQ MAZE traded down $0.49 during mid-day trading on Tuesday, hitting $12.23. The company had a trading volume of 141,658 shares, compared to its average volume of 324,193. Maze Therapeutics has a 1-year low of $10.08 and a 1-year high of $17.00.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
